ZKY001 / Zhaoke Ophthalmology - LARVOL DELTA

ZKY001 With Different Concentrations in the Treatment of Corneal Epithelial Defect After Primary Pterygium Excision: A Multicenter, Randomized, Double-Masked Phase 2 Study (AAO 2024) - "And the treatment-emergent adverse event rate was low (9.0%), with no significant difference . Conclusion ZKY001 can effectively improve CED and relieve foreign body sensation and pain after primary pterygium surgery, providing a new treatment for promoting corneal repairment and relieving discomfort."

Clinical • P2 data • Ophthalmology

ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects in a Phase Ⅱ Clinical Trial (clinicaltrials.gov) - P2 | N=180 | Completed | Sponsor: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

New P2 trial

TPRK: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of ZKY001 Eye Drops (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

New P2 trial

Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects (clinicaltrials.gov) - P2; N=105; Recruiting; Sponsor: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.; Trial primary completion date: Jan 2021 ➔ Dec 2021

Clinical • Trial primary completion date • Transplantation

Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects (clinicaltrials.gov) - P2; N=105; Recruiting; Sponsor: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.; Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Oct 2020 ➔ Jan 2021

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Transplantation

Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects (clinicaltrials.gov) - P2; N=105; Not yet recruiting; Sponsor: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.; Initiation date: Apr 2020 ➔ Jul 2020

Clinical • Trial initiation date • Ophthalmology • Transplantation

Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects (clinicaltrials.gov) - P2; N=105; Not yet recruiting; Sponsor: Lee's Pharmaceutical Limited

Clinical • New P2 trial